Regenxbio (STU:RB0) Cyclically Adjusted FCF per Share: €-2.24 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:RB0 Regenxbio Inc STU:RB0
57 GF Score
Price €8.62
GF Value €13.00
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Regenxbio Cyclically Adjusted FCF per Share?

Regenxbio STU:RB0 -11.15% 57 Cyclically Adjusted FCF per Share is €-2.24 as of Mar. 2026. GuruFocus rates STU:RB0 with a GF Score™ of 57/100 and a GF Value™ of €13.00 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Regenxbio's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-1.277. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-2.24 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-19), Regenxbio's current stock price is €8.618. Regenxbio's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-2.24. Regenxbio's Cyclically Adjusted Price-to-FCF of today is .


Regenxbio  (STU:RB0) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Regenxbio Cyclically Adjusted FCF per Share Related Terms


Regenxbio Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Regenxbio's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenxbio Cyclically Adjusted FCF per Share Chart

Regenxbio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.25 -2.05

Regenxbio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.24 -2.10 -2.06 -2.05 -2.24

STU:RB0 vs ALT, ASMB, CTNM: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Regenxbio's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenxbio Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Regenxbio's Cyclically Adjusted Price-to-FCF falls into.


STU:RB0
57GF Score
Regenxbio Inc STU:RB0
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regenxbio Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regenxbio's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.277/330.2130*330.2130
=-1.277

Current CPI (Mar. 2026) = 330.2130.

Regenxbio Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.321 241.018 -0.440
201609 -0.473 241.428 -0.647
201612 -0.890 241.432 -1.217
201703 -0.715 243.801 -0.968
201706 -0.326 244.955 -0.439
201709 -0.477 246.819 -0.638
201712 -0.431 246.524 -0.577
201803 1.320 249.554 1.747
201806 1.639 251.989 2.148
201809 -0.578 252.439 -0.756
201812 -0.204 251.233 -0.268
201903 -0.773 254.202 -1.004
201906 -0.707 256.143 -0.911
201909 -0.785 256.759 -1.010
201912 -0.647 256.974 -0.831
202003 -0.981 258.115 -1.255
202006 -0.590 257.797 -0.756
202009 -0.929 260.280 -1.179
202012 0.584 260.474 0.740
202103 -1.508 264.877 -1.880
202106 -1.092 271.696 -1.327
202109 -1.220 274.310 -1.469
202112 5.943 278.802 7.039
202203 -1.414 287.504 -1.624
202206 -1.558 296.311 -1.736
202209 -1.296 296.808 -1.442
202212 -0.978 296.797 -1.088
202303 -1.843 301.836 -2.016
202306 -1.058 305.109 -1.145
202309 -1.084 307.789 -1.163
202312 -0.873 306.746 -0.940
202403 -1.127 312.332 -1.192
202406 -0.844 314.175 -0.887
202409 -0.725 315.301 -0.759
202412 -0.614 315.605 -0.642
202503 0.586 319.799 0.605
202506 -0.838 322.561 -0.858
202509 -0.930 324.800 -0.945
202512 -0.871 324.054 -0.888
202603 -1.277 330.213 -1.277

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-2.24 mean?
Regenxbio (STU:RB0) has a Cyclically Adjusted FCF per Share of €-2.24 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Regenxbio and its competitors.
Is Regenxbio's Cyclically Adjusted FCF per Share too high?
Regenxbio's current Cyclically Adjusted FCF per Share is €-2.24. Overall, Regenxbio has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Regenxbio's Cyclically Adjusted FCF per Share compare to ALT and ASMB?
Regenxbio's Cyclically Adjusted FCF per Share of €-2.24 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Regenxbio and its competitors. Regenxbio's current Cyclically Adjusted FCF per Share is €-2.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenxbio stock overvalued right now?
Based on GuruFocus' analysis, Regenxbio (STU:RB0) is currently considered Possible Value Trap. The stock's GF Value™ is €13.00, compared to a current price of €8.62 — trading 33.7% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-2.24. Regenxbio's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Regenxbio (STU:RB0), the current Cyclically Adjusted FCF per Share is €-2.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regenxbio (STU:RB0) Overvalued in 2026?

Based on GuruFocus' analysis, Regenxbio stock appears to be undervalued. The current stock price of €8.62 is trading 33.7% below its estimated GF Value™ of €13.00. GuruFocus considers Regenxbio to be Possible Value Trap.

Key valuation signals for STU:RB0:

  • Cyclically Adjusted FCF per Share: €-2.24
  • GF Value™: €13.00 vs. price of €8.62 (33.7% below fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the STU:RB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Regenxbio Business Description

Other Exchanges RGNX:USA
Address 9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
57GF Score

Get the complete analysis for STU:RB0

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.62
Price
€13.00
GF Value